Freda Miller of the Hospital for Sick Children and University of Toronto and colleagues published their findings in the April 19, 2007 issue of the journal Neuron, published by Cell Press.
NS is a relatively common genetic disorder, occurring in one of every 2,500 live births. It is characterized by congenital heart defects, short stature, learning disabilities, and mental retardation. Approximately 50% of NS cases are caused by a genetic mutation in a biochemical switch called SHP-2. SHP-2 is involved in molecular pathways regulating development of brain cells. The NS mutations cause SHP-2 to be constantly activated.
Specifically, SHP-2 plays a role in the pathways governing differentiation of immature precursor cells into neurons and glial cells. Unlike neurons, which conduct nerve impulses, glial cells are supporting cells that surround neurons and insulate them from one another.
In experiments with cultured precursor cells, the researchers found that SHP-2 activates the regulatory pathway that causes genesis of neurons and inhibits the pathway that generates glial cells. And in experiments with both cell cultures and mouse embryos, they found that the same kind of mutation in SHP-2 that can be found in NS patients disrupts the neuron-glial balance by further promoting the formation of neurons and inhibiting glial cell formation.
The researchers also studied the effects of the mutation in mice engineered to mimic the human disorder. Like humans with NS,